share_log

Oppenheimer Initiates Coverage On Sagimet Biosciences With Outperform Rating, Announces Price Target of $30

Oppenheimer Initiates Coverage On Sagimet Biosciences With Outperform Rating, Announces Price Target of $30

Oppenheimer启动对Sagimet Biosciences的覆盖,并给予Outperform评级,宣布目标股价为30美元。
Benzinga ·  2024/12/06 06:16  · 评级/大行评级

Oppenheimer analyst Jay Olson initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Outperform rating and announces Price Target of $30.

Oppenheimer的分析师Jay Olson开始对Sagimet Biosciences(纳斯达克:SGMT)进行覆盖,给予其优于大盘的评级,并宣布目标价格为30美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发